COSCIENS Biopharma Keeps Debenture Offering Open: Conversion Would Give Noteholders Two-Thirds

November 14, 2026:

COSCIENS Biopharma Keeps Debenture Offering Open: Conversion Would Give Noteholders Two-Thirds
COSCIENS Biopharma
Cosciensbiopharma.com

COSCIENS Biopharma, the Toronto company that bought oral-film maker Nualtis Corp. on Sept. 10, said Friday it will keep its debenture offering open until Nov. 30. Conversion at $7.00 per unit would turn the roughly $14.3 million raised so far into about 2.04 million new shares and as many warrants. Calculated from that price and the 997,219 shares outstanding when the Nualtis deal closed, noteholders would own about two-thirds of the company before any warrant is exercised. Current shareholders will vote on the terms at a meeting COSCIENS now expects in January 2027.

The update arrived with third-quarter results. COSCIENS reported a net loss of $3.4 million, or $3.45 per share, against $1.8 million a year earlier. The loss included a $2.0 million non-cash write-down of PGX equipment and $1.1 million of costs tied to the Nualtis acquisition and its financing. Revenue rose to $2.5 million from $1.5 million on higher active-ingredient volumes, and gross margin reached 55% against 42%. Cash stood at $9.2 million on Sept. 30, and the release does not say how proceeds from the debenture closings are reflected in that balance.

The same release says a rizatriptan oral thin film made by Nualtis and partnered with Gensco Pharma is expected to launch in the fourth quarter. That is a rollout of an FDA-approved product, not a pending approval, but its launch date has moved before, and its speed advantage over tablets is thinner in FDA documents than in marketing. The sections below cover the share math, the film’s technology, and what the quarter did and did not change.

Debenture Conversion at $7.00 Would Hand Noteholders About Two-Thirds of COSCIENS

The debentures pay 15% a year in cash each month, mature Sept. 10, 2027 and are capped at $20 million. About $14.3 million has closed, with three further closings on Oct. 7, Oct. 16 and Nov. 12 following two earlier closings that totaled $10.6 million. The Toronto Stock Exchange has conditionally approved converting each debenture into units at $7.00. Each unit holds one common share and one warrant exercisable at $7.00 until Sept. 10, 2031, and accrued interest does not convert. Conversion requires shareholder and exchange approval, and the company has agreed to call a meeting by March 10, 2027. In its Oct. 19 update, it had pointed to December.

Friday’s release gives no share count. The Sept. 10 announcement put shares outstanding at 997,219. The roughly $27 million pro forma market value COSCIENS cited on Oct. 19 for a full $20 million raise equals about 3.85 million shares at $7.00, which fits that base. On those numbers, $14.3 million of principal converts into about 2.04 million shares, lifting the total to about 3.04 million. A full $20 million raise would yield about 2.86 million shares and a total near 3.85 million. Exercising every warrant at $7.00 would add the same number again and cut today’s holders to roughly 20% at $14.3 million, or 15% at $20 million. These are TechTimes calculations from the company’s disclosed figures.

Directors and officers of COSCIENS and Nualtis, or related entities, supplied about $2.6 million of the total, or 18%. The Sept. 10 terms also carried a ratchet lowering the conversion price if COSCIENS issues equity below $7.00. Friday’s release says only that the price and warrants are subject to adjustment, and it does not say whether the ratchet survives. Reset features in convertible financing, sometimes called death-spiral convertible financing, can raise the share count most when the stock is weakest.

The cash coupon is the other cost. Interest on $14.3 million at 15% comes to about $2.1 million a year, or $179,000 a month, against Q3 gross profit of $1.4 million, or roughly $467,000 a month, by TechTimes calculation. CFO Giuliano La Fratta said COSCIENS believes it is well positioned to achieve profitability. On Oct. 19 the company said money raised to date plus existing cash already covered the $6 million due to AtaiBeckley in March 2027, and that full conversion of a $20 million raise would leave more than $7 million in cash and no debt.

Does RizaFilm Work Faster Than Rizatriptan Tablets?

When the FDA approved the film in April 2023, Andre Godin, then president and CFO of developer IntelGenx, told Formulary Watch it was the fastest triptan on the market, Drug Topics reported. FDA documents describe a narrower case. The agency’s review says RizaFilm meets bioequivalence criteria with the 10 mg Maxalt-MLT orally disintegrating tablet. The label lists a film peak blood-level time of about 1.4 hours, against 1 to 1.5 hours for the tablet and up to 0.7 hour later than the tablet for the orally disintegrating version. The label also says the film’s efficacy rests on a relative bioavailability study against the 10 mg tablet.

The mechanism explains why. RizaFilm is a 10 mg rizatriptan film, a rectangle about 2.2 by 2.75 centimeters (0.87 by 1.08 inches), placed on the tongue, where it disintegrates in about two minutes and can be swallowed with saliva, per its label. Many orally disintegrating tablets are absorbed mainly through the digestive tract, like standard pills. Belbuca, the buprenorphine film that Nualtis’s generic candidate targets, is built for a different buccal route: the drug crosses the lining of the cheek. The label says no liquid is needed, and Practical Neurology called the film well suited to the roughly 80% of patients who have migraine-related nausea.

The format has engineering limits. Nualtis’s VersaFilm platform dissolves the drug with film-forming agents, spreads the solution onto a carrier, dries it and cuts it, and Manufacturing Chemist cited about 50 mg of drug per film as a typical ceiling. A peer-reviewed pharmaceutical review article of orodispersible films also cites limited drug loading, stability issues and industrial scale-up challenges. Rizatriptan carries clinical constraints too. The label contraindicates propranolol and says dose adjustment is not possible with the film, and the 2023 pediatric label covers ages 12 to 17 weighing 40 kilograms (88 lbs) or more.

RizaFilm Has Carried Three U.S. Launch Targets Since 2023, Now Fourth Quarter

Gensco, which holds the NDA, said in September 2023 that it anticipated launching RizaFilm in the first quarter of 2024. In May 2025 it announced the purchase of global rights and said it was preparing a U.S. launch for the fourth quarter of 2025. COSCIENS’s Sept. 10 announcement then cited a Gensco launch in October 2026. Friday’s release, published after October ended, still describes the launch as expected in the fourth quarter.

The approval path was also long. FDA records show complete response letters on Jan. 31, 2014 and March 28, 2019 before the April 2023 approval. COSCIENS says a 5 mg pediatric strength was approved in February 2026. Nualtis was formerly IntelGenx, which rebranded in June 2025 after going through Canadian creditor-protection proceedings and a sale to atai Life Sciences in October 2024.

The deal terms matter for how much of this accrues to COSCIENS. The price is $15 million: $9 million in cash at closing and a non-interest-bearing $6 million due by March 10, 2027. Earn-out payments follow for 2027 through 2030, up to four of them, each equal to 10% of Nualtis EBITDA. Gensco owns the global rights to RizaFilm and Nualtis is the manufacturer. CEO Peter Puccetti said Nualtis has the potential to generate tens of millions of dollars in annual revenue and an EBITDA margin of roughly 40% at scale, but the release gives no figures behind that, and Nualtis contributed only 20 days to Q3.

Generic Belbuca Candidate Faces Two FDA Rejections and Patent Litigation

COSCIENS also points to a generic version of Belbuca, a buprenorphine buccal film for chronic pain that posted $221.7 million in U.S. net revenue in 2025. Nualtis develops and manufactures it with Chemo Research and its U.S. affiliate Xiromed, which handles approval and sales, and no U.S. generic has launched.

The application has struggled. As of April 2024, the FDA had issued two complete response letters, the second asking for more pharmaceutical quality information. Two Belbuca drug-product patents run to July 2027, a third could extend exclusivity to December 2032, and an infringement suit filed by Collegium’s BioDelivery Sciences affiliate in Delaware federal court was ongoing. Those details are more than two and a half years old, and the Sept. 10 release says only that no U.S. generic has launched.

PGX Write-Down Cuts Equipment Value to $0.2M and Narrows Ceapro to Oat Extraction

Ceapro, COSCIENS’s Alberta oat-ingredients subsidiary, took the $2.0 million impairment after shifting its development focus to process improvements in oat extraction. The charge cut the PGX equipment’s carrying value to $0.2 million, does not affect cash, and leaves the equipment in place for research. PGX, short for Pressurized Gas eXpanded, converts liquid beta-glucan into dry microfibrils or free-flowing powder with adjustable particle size, and Ceapro’s Gilles Gagnon once said it could be a major game-changer for the company. Ceapro executive Mitch Regnier said sales and operational improvements have put the unit back on a path to sustained growth and profitability.

The nine-month picture needs the same care. COSCIENS booked net income of $7.1 million, but $10.9 million of that came from discontinued operations after it deconsolidated its German subsidiaries. Net loss from continuing operations narrowed to $3.8 million from $6.3 million. The subsidiaries had filed for insolvency in Germany in March.

Shareholder Vote Expected in January Sets Dilution Terms Before Nualtis Earnings Arrive

The decision points are dated. The offering stays open to Nov. 30 unless the maximum is reached sooner, with at least one more closing expected but not assured. The shareholder vote follows in January, the $6 million payment falls due by March 10, 2027, and the debentures mature Sept. 10, 2027.

For anyone weighing the stock, the full picture has five parts. Conversion at $7.00 would roughly triple the share count, with matching warrants behind it. The 15% cash coupon takes a large share of current gross profit. RizaFilm is approved, but its launch has slipped across three targets and FDA records support bioequivalence to tablets rather than faster relief. The Belbuca generic still faces a quality-review hurdle and patent litigation as of the latest public record. The PGX write-down is non-cash, yet it marks down a technology Ceapro’s Gilles Gagnon once said could be a major game-changer. The circular for the January meeting should show whether the price protections survived and what conversion would cost current holders.


Frequently Asked Questions

How many new shares could COSCIENS issue if the debentures convert?

About 2.04 million for the roughly $14.3 million raised so far, and about 2.86 million if the full $20 million is raised, each paired with a warrant, against 997,219 shares outstanding on Sept. 10. These are TechTimes calculations from the $7.00 conversion price.

Is RizaFilm already approved by the FDA?

Yes. The FDA approved the 10 mg film in April 2023 for adults and for patients ages 12 to 17 weighing at least 40 kilograms (88 lbs), and COSCIENS says a 5 mg pediatric strength followed in February 2026. Gensco is expected to launch it in the fourth quarter.

What is an oral thin film?

A polymer strip that carries a drug and disintegrates on the tongue without water. RizaFilm disintegrates in about two minutes, and Manufacturing Chemist has cited about 50 mg of drug per film as a typical ceiling.

Does the PGX write-down reduce COSCIENS’s cash?

No. The $2.0 million impairment is non-cash and lowered the equipment’s carrying value to $0.2 million.

Source link